Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.22 +3.01%

+$0.81 today

Market cap
$1.76B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 3.12M

Average 1.81M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$466.00M

FY 2025 · Annual

Investing Cash Flow

$236.00M

FY 2025 · Annual

Financing Cash Flow

$478.00M

FY 2025 · Annual

+19.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(454.03M)(707.42M)(606.64M)(569.18M)(575M)
Depreciation & Amortization13.24M18.22M26.01M35.54M35M
Deferred Income Tax48.67M0(1.62M)00
Stock-Based Compensation104.95M130.38M135.21M158.03M153M
Change in Working Capital(63.24M)60.24M(15.1M)13.92M(23M)
Accounts Receivables(5.43M)(12.07M)(22.78M)(33.6M)(31M)
Inventory(3.12M)(9.7M)(6.93M)(11.21M)(6M)
Accounts Payables2.81M79.85M2.38M46.99M24M
Other Working Capital(57.49M)2.16M12.23M11.73M(10M)
Other Non-Cash Items11.71M118.12M(12.67M)(52.5M)(56M)
Operating Cash Flow(338.7M)(380.47M)(474.81M)(414.19M)(466M)
Capital Expenditures(73.09M)(146.12M)(46.77M)(7.49M)(6M)
Acquisitions (Net)0(75.03M)000
Purchases of Investments(1.01B)(614.74M)(526.38M)(408.61M)(186M)
Sales of Investments890.85M545.08M746.2M413.27M444M
Other Investing Activities(942K)(30.84M)(7.55M)(14.94M)(16M)
Investing Cash Flow(195.37M)(291.65M)168M(17.77M)236M
Debt Repayment0000392M
Common Stock Issued78.94M0379.76M380.98M86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities39.61M501.21M8.39M18.26M0
Financing Cash Flow118.55M501.21M388.14M399.24M478M
Effect of Forex Changes(1.19M)(1.08M)462K(2.53M)5.47M
Net Change in Cash(416.71M)(171.98M)81.8M(35.24M)253.47M
Free Cash Flow(411.79M)(526.59M)(521.57M)(421.68M)(472M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$575.0M
+ D&A$35.0M
+ Stock-Based Comp$153.0M
+ Deferred Tax$0
- Working Capital-$23.0M
- Other Non-Cash-$56.0M
= Operating Cash Flow-$466.0M
- Capex-$6.0M
= Free Cash Flow-$472.0M

Analysis

FY2025 free cash flow is -$472.0M. FCF conversion is 82.1% of net income. Operating cash flow was -$466.0M, with capex of -$6.0M. The largest bridge item is Stock-Based Comp at $153.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 3, 2026
SC 13G/ASC 13G/A filingOct 30, 2026

Does RARE generate free cash flow?

Ultragenyx Pharmaceutical Inc. (RARE) generated -$472.00M of free cash flow in fiscal 2025.

How much operating cash flow does RARE produce?

Operating cash flow was -$466.00M, before capital expenditures of $6.00M.